123 studies found for:    PTEN
Show Display Options
Rank Status Study
1 Recruiting A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
Condition: Cancer
Intervention: Drug: GSK2636771
2 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
3 Withdrawn PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
Condition: Ovarian Cancer
Intervention: Procedure: immunohistochemical, methylation, gene transfection
4 Completed
Has Results
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Conditions: Cowden's Disease;   Hamartoma Syndrome, Multiple
Interventions: Radiation: fludeoxyglucose F 18;   Drug: sirolimus;   Other: Clinical Videography
5 Recruiting Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Condition: c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Deletion of PTEN or PTEN Negative by IHC, INC280, BKM120, Buparlisib; Recurrent Glioblastoma
Interventions: Drug: INC280;   Drug: Buparlisib
6 Recruiting Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients
Conditions: Critical Illness;   Hyperglycemia
Intervention:
7 Recruiting Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
Condition: Breast Cancer
Intervention: Genetic: BRCA1 BRCA2 PTEN PALB2 mutation
8 Recruiting AZD8186 First Time In Patient Ascending Dose Study
Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);;   Squamous Non-Small Cell Lung Cancer (sqNSCLC);;   Triple Negative Breast Cancer (TNBC)
Intervention: Drug: AZD8186
9 Active, not recruiting Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Pazopanib;   Drug: Everolimus
10 Unknown  Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
Condition: Prostate Cancer
Intervention:
11 Unknown  Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?
Conditions: Low Ovarian Reserve;   Poor Responders to Gonadotropihins Treatment
Intervention: Other: Removal of half an ovary
12 Completed
Has Results
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: RAD001
13 Recruiting Genetics, Brain Structure and Thinking Skills in Autism
Condition: Autism Spectrum Disorders
Intervention:
14 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
15 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Terminated
Has Results
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Condition: Adult Brain Tumors
Intervention: Drug: erlotinib hydrochloride
17 Terminated
Has Results
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme
Interventions: Drug: Everolimus;   Procedure: Surgery
18 Active, not recruiting
Has Results
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Condition: Metastases, Brain
Interventions: Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab
19 Completed Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
Condition: Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: FOLFIRI
20 Recruiting DNA Analysis of Tumor Tissue Samples From Patients With Recurrent or Metastatic Breast Cancer That Expresses HER2
Condition: Breast Cancer
Interventions: Genetic: comparative genomic hybridization;   Genetic: fluorescence in situ hybridization;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Procedure: biopsy;   Procedure: histopathologic examination

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years